CLVS Research and Charts

CLVS - Clovis Oncology Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2023-05-29 (Delayed quote data )

Last	Change ⇓ 0.00 (%)	Volume 0
	Open	High	Low

8EMA (Daily) 0.00	40EMA (Daily)	50EMA (Daily)	STO (Daily)	MACD Hist (Daily)
8EMA (Weekly) 0.289	40EMA (Weekly) 1.32	50EMA (Weekly) 1.62	STO (Weekly) 1.618	MACD Hist (Weekly) -0.069


Company Profile
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.